Tagged with Reimbursement

Diane Kleinermans – President, Commission for the Reimbursement of Medicines, NIHDI, Belgium
Switzerland’s Upcoming Cost Containment Packages: Industry Key Concerns
China’s National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Cross Country Collaborations in Europe: The Future of Pricing & Access Negotiations?
Novartis Oncology President: “If We Offer Pay-For-Performance, Healthcare Systems Should Use It!”
Market Access in Switzerland: Reimbursement Delays for 76% of New Products Undermining Innovation Reputation
Overcoming US Pricing & Reimbursement Challenges
Martin Mátl – Executive Director, ČAFF, Czech Republic
Mattias Bankel – General Manager, Head of Nordics & Baltics, Amicus Therapeutics
Chinese PD-1 Cancer Drugs: Global Competition for Big Pharma
Forging a New Path to Commercialization for Cell and Gene Therapies
Shooting For the Stars: The Evolution in Outcome-Based Payment Models for Medicines
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here